We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The US Food and Drug Administration (FDA) has approved the use of Pfizer’s anticoagulant medicine Fragmin (dalteparin sodium) to minimise the recurrence of symptomatic venous thromboembolism (VTE) in paediatric patients aged one month and above.